This study is testing a new medicine called tegavivint for kids and young adults with certain tumors that haven’t gone away with other treatments. Tumors are lumps of cells that grow too much and can make you sick. Tegavivint works by stopping signals that tell these cells to grow. The study is in two parts: first to find out the best safe dose and then to see how well it works.
Participants will get tegavivint through IV (intravenous) infusion for 4 hours once a week for 3 weeks, followed by a week off. This will happen over a month-long cycle and can continue for up to 24 months if necessary. The study will check side effects and see if the tumors shrink. Patients will have tests like x-rays and scans regularly to monitor the treatment's effects.
- Trial involves regular hospital visits for up to 2 years.
- Participants must be between 1-30 years old with certain types of tumors.
- Must not have tried tegavivint before or have major bone problems.